Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay

Pathology Research and Practice

Volumn 209, Issue 4, 2013, Pages 233-236

  Miglio, Umberto ^a   Mezzapelle, Rosanna ^a,b   Paganotti, Alessia ^c   Allegrini, Sara ^a   Veggiani, Claudia ^c   Antona, Jlenia ^a   Gentilli, Sergio ^a   Monga, Guido ^a,c   Alabiso, Oscar ^a   Boldorini, Renzo ^a,c  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Laboratory of Cancer Genomics   (Italy)

^c MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Colorectal cancer; KRAS gene; Mutational analysis

Indexed keywords

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; HUMAN TISSUE; INGUINAL LYMPH NODE; KRAS MUTATION KIT; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MUTATIONAL ANALYSIS; ONCOGENE K RAS; TRANSBRONCHIAL ASPIRATION; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TIME FACTORS;

EID: 84876334891     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.02.006     Document Type: Article

References (33)

1. Allegrini S., Antona J., Mezzapelle R., Miglio U., Paganotti A., Veggiani C., Frattini M., Monga G., Balbo P., Boldorini R. Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. Am. J. Clin. Pathol. 2012, 138:377-381.
2. Anderson S.M. Laboratory methods for KRAS mutational analysis. Expert Rev. Mol. Diagn. 2011, 11:635-642.
3. Artale S., Sartore-Bianchi A., Veronese S.M., Gambi V., Sarnataro C.S., Gambacorta M., Lauricella C., Siena S. Mutations of KRAS and BRAF in primary and marche metastatic sites of colorectal cancer. J. Clin. Oncol. 2008, 26:4217-4219.
4. Baldus S.E., Schaefer K.L., Engers R., Hartleb D., Stoecklein N.H., Gabber H.E. Prevalence and heterogeneity of KRAS BRAF, and PIK3CA mutations in primary adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 2010, 16:790-799.
5. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancer to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
6. Borras E., Jurado I., Hernan I., Gamundi M.J., Dias M., Martí I., Mañé B., Arcusa A., Agúndez J.A., Blanca M., Carballo M. Clinical pharmacogenomic testing of KRAS BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 2011, 11:406.
7. Bouchahda M., Karaboué A., Saffroy R., Innominato P., Gorden L., Guettier C., Adam R., Lévi F. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother. Pharmacol. 2010, 66:605-609.
8. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
9. Do H., Krypuy M., Mitchell P.L., Fox S.B., Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008, 8:142.
10. Dufort S., Richard M.J., De Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal. Biochem. 2009, 391:166-168.
11. Etienne-Grimaldi M.C., Formento J.L., Francoual M., François E., Formento P., Renée N., Laurent-Puig P., Chazal M., Benchimol D., Delpero J.R., Letoublon C., Pezet D., Seitz J.F., Milano G. K-ras mutations and treatment out come in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res. 2008, 14:4830-4835.
12. European Medicine Agency Available from:. http://www.emea.europa.eu/.
13. FDA U.S. Food and drug administration: Cetuximab (Erbitux) and Panitumumab (vectibux). Available from:. http://fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm.
14. Gibson T.B., Ranganathan A., Grothey A. Randomized phase III trial results of panitumumab a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6:29-31.
15. Gonzalez de Castro D., Angulo B., Gomez B., Mair D., Martinez R., Suarez-Gauthier A., Shieh F., Velez M., Brophy V.H., Lawrence H.J., Lopez-Rios.F. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br. J. Cancer 2012, 107:345-351.
16. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics. CA. Cancer J. Clin. 2008, 58:71-96.
17. Jimeno A., Messersmith W.A., Hirsch F.R., Franklin W.A., Eckhardt S.G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 2009, 27:1130-1136.
18. Knijn N., Mekenkamp L.J.M., Klomp M., Vink-Börger M.E., Tol J., Teerenstra S., Meijer J.W., Tebar M., Riemersma S., Van Krieken J.H., Punt C.J., Nagtegaal I.D. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br. J. Cancer 2011, 104:1020-1026.
19. Lièvre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., Laurent-Puig.P. KRAS mutation as an indipendent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
20. Lièvre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Côté J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig.P. KRAS mutation status is predictive to response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
21. Molinari F., Frattini M. KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem. Expert Rev. Mol. Diagn. 2012, 12:123-126.
22. Molinari F., Martin V., Saletti P., De Dosso S., Spitale A., Camponovo A., Bordoni A., Crippa S., Mazzucchelli L., Frattini M. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br. J. Cancer 2009, 100:1087-1094.
23. Nash G.M., Gimbel M., Shia J., Nathanson D.R., Ndubuisi M.I., Zeng Z.S., Kemeny N., Paty P.B. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann. Surg. Oncol. 2010, 17:572-578.
24. Oliveira C., Velho S., Moutinho C., Ferreira A., Preto A., Domingo E., Capelinha A.F., Duval A., Hamelin R., Machado J.C., Schwartz S., Carneiro F., Seruca R. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007, 26:158-163.
25. Oliveira C., Westra J.L., Arango D., Ollikainen M., Domingo E., Ferreira A., Velho S., Niessen R., Lagerstedt K., Alhopuro P., Laiho P., Veiga I., Teixeira M.R., Ligtenberg M., Kleibeuker J.H., Sijmons R.H., Plukker J.T., Imai K., Lage P., Hamelin R., Albuquerque C., Schwartz S., Lindblom A., Peltomaki P., Yamamoto H., Aaltonen L.A., Seruca R., Hofstra R.M. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum. Mol. Genet. 2004, 13:2303-2311.
26. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu Tumorigenesis V.E. RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
27. Santini D., Loupakis F., Vincenzi B., Floriani I., Stasi I., Canestrari E., Rulli E., Maltese P.E., Andreoni F., Masi G., Graziano F., Baldi G.G., Salvatore L., Russo A., Perrone G., Tommasino M.R., Magnani M., Falcone A., Tonini G., Ruzzo A. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implication for clinical practice. Oncologist 2008, 13:1270-1275.
28. Scaltrini M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12:5268-5272.
29. Scoggan K.A., Bulman D.E. Single-strand conformational polymorphism analysis (SSCP) and sequencing for ion channel gene mutations. Methods Mol. Biol. 2003, 217:143-151.
30. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., Richel D.J., Voest E.E., Dijkstra J.R., Vink-Börger M.E., Antonini N.F., Mol L., van Krieken J.H., Dalesio O., Punt C.J. Chemotherapy bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:563-572.
31. Tórtola S., Steinert R., Hantschick M., Peinado M.A., Gastinger I., Stosiek P., Lippert H., Schlegel W., Reymond M.A. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J. Clin. Oncol. 2001, 19:2837-2843.
32. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal tumour development. N. Engl. J. Med. 1988, 319:525-532.
33. Watanabe T., Kobunai T., Yamamoto Y., Matsuda K., Ishihara S., Nozawa K., Iinuma H., Shibuya H., Eshima K. Heterogenity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis. Colon Rectum 2011, 54:1170-1178.